Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed hepatocellular carcinoma~  * Confirmed by needle aspirate, biopsy, or prior surgical resection specimen~* Clinically confirmed hepatocellular carcinoma defined as follows:~  * Cirrhosis or chronic hepatitis B or C virus infection, with 1 or more hypervascular liver masses more than 2 cm~ * Alpha-fetoprotein (AFP) greater than 400 ng/mL OR greater than 3 times normal and doubling in value during the past 3 months~* Deemed unresectable~  * Prior surgical resection allowed~ * Recurrence after hepatic resection or other procedure allowed~ * Tumor that extends into branches of the portal or hepatic veins allowed~ * No tumor invading the main portal vein (portal trunk) or inferior vena cava~ * No tumor occupying more than 50% of the liver volume~* Enlargement/involvement of regional lymph nodes allowed~* At least 1 unidimensionally measurable lesion at least 20 mm~  * No poorly defined lesions~ * No vague hypervascular patches~* Child-Pugh class A or compensated Child-Pugh class B liver dysfunction~  * No Child-Pugh class C or uncompensated class B indicated by active encephalopathy, persistent ascites, or prothrombin time greater than 1.5 times normal~ * Prior ascites allowed if manageable with diuretics alone~ * No repeated paracentesis (more than 1 per month)~* No extrahepatic metastasis~* No documented brain metastases~* No history or clinical evidence of CNS disease (e.g., primary brain tumor, seizures uncontrolled with standard medical therapy, or history of stroke)~* Performance status - ECOG 0-2~* Absolute neutrophil count greater than 1,500/mm\^3~* Hemoglobin at least 8 g/dL~* Platelet count at least 75,000/mm\^3~* No prior serious bleeding event (unrelated to liver disease)~* No bleeding diathesis~* No coagulopathy~* Bilirubin no greater than 3 mg/dL~* Transaminases less than 5 times upper limit of normal (ULN)~* Albumin at least 2.5 mg/dL~* PTT less than 4 seconds above ULN~* INR less than 1.5 (for patients receiving warfarin)~* Creatinine less than 1.5 g/dL~* Urine protein less than 500 mg/24hrs\*~Exclusion criteria:~* No thromboembolic event within the past 12 months~* No clinically significant cardiovascular disease~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active infection requiring parenteral antibiotics~* No serious non-healing wound/ulcer or bone fracture~* No variceal bleeding within the past 6 months~* No malignancy within the past 5 years except localized nonmelanoma skin cancer~* No ongoing psychiatric or social situation that would preclude study compliance~* No known hypersensitivity to Chinese hamster ovary cell products~* No known hypersensitivity to other recombinant human antibodies~* No more than 1 prior biologic therapy~* No concurrent interferon~* No concurrent interleukin-2~* No more than 1 prior antineoplastic chemotherapy~* At least 4 weeks since prior invasive surgery, including open biopsy~* At least 2 weeks since prior needle biopsy (core or fine-needle aspirate)~* No concurrent hepatic transplant~* At least 4 weeks since prior anticancer therapy~* No concurrent platelet-stimulating factors (e.g., oprelvekin)~* No concurrent full-dose anticoagulants or thrombolytic agents (except as required to maintain patency of pre-existing, permanent indwelling IV catheters)~* No chronic daily antiplatelet drugs (e.g., aspirin doses of 325 mg/day or higher or non-steroidal anti-inflammatory drugs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (bevacizumab) (Type: EXPERIMENTAL): Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment continues every 2 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).